Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
PR Newswire•06/10/2026•19:30 ET
0
Key Highlights
- ➤Astellas will present 21 oncology abstracts at ESMO 2026, spanning five cancer types
- ➤PADCEV plus pembrolizumab includes longest reported follow-up in advanced urothelial cancer
- ➤VYLOY studies reinforce CLDN18.2-guided treatment decisions in gastric and GEJ cancers
- ➤Setidegrasib Phase 3 trials target KRAS G12D-mutated pancreatic and lung cancers
- ➤ASP546C and ASP5834 trials expand Astellas's investigational solid-tumor pipeline
Expert Statements
Moitreyee Chatterjee-Kishore, Executive Vice President and Head of Oncology Development, Astellas
“Standards of care do not change by accident. The data being presented at ESMO 2026 demonstrate how a deep understanding of disease biology and differentiated modalities is helping advance care for patients with bladder, gastric, and prostate cancers, including through approaches such as PADCEV™ (enfortumab vedotin) plus pembrolizumab, VYLOY™ (zolbetuximab), and XTANDI™ (enzalutamide). We are building upon this knowledge to develop the next generation of therapeutic options for cancers where unmet needs remain and look forward to engaging in discussions about this work at the congress.”
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026 PR Newswire
– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –
Get started
Create a free account to read the full story.